Skip to content
PubMed This is a summary of 10 peer-reviewed journal articles Updated
Hematology

Is Myelofibrosis Hereditary? Should Relatives Be Tested?

At a Glance

Myelofibrosis is usually caused by genetic changes acquired during life, so it is not passed directly to children and relatives generally do not need genetic testing. Genetic counseling may be appropriate after an unusually young diagnosis, a strong family history, or when assessing a stem cell donor.

For the vast majority of people, myelofibrosis is not hereditary. It is an acquired condition, meaning it develops during your lifetime and is not passed down directly from parent to child [1]. While it is entirely natural to worry about your family’s health after a diagnosis, relatives of someone with myelofibrosis do not generally need routine genetic testing unless specifically recommended by a specialist [2].

Acquired vs. Inherited Mutations

To understand why myelofibrosis is usually not hereditary, it helps to know the difference between two types of genetic mutations: somatic and germline.

  • Somatic (acquired) mutations: These are genetic changes that happen in specific cells during your lifetime. In myelofibrosis, the genetic mutations that drive the disease—most commonly in the JAK2, CALR, or MPL genes—are somatic [1][3]. They occur in your blood-forming cells and the blood cells they produce, but not in your reproductive cells (sperm or eggs). Because they are not in your reproductive cells, you cannot pass these specific disease-driving mutations on to your children [1]. When a mutation is found on a standard bone marrow or blood cancer panel, it is usually one of these acquired changes, not an inherited trait.
  • Germline (inherited) mutations: These are genetic changes you are born with. They exist in every cell of your body and can be passed to your children. While there are some rare inherited genetic variations that can increase a person’s chances of developing a blood cancer, these are distinct from the typical acquired mutations that cause myelofibrosis [4][3].

Familial Risk and Predisposition

Although you do not pass myelofibrosis directly to your children, researchers have noted that blood cancers like myeloproliferative neoplasms (MPNs) can sometimes run in families, a concept known as familial clustering [5].

Instead of inheriting the disease itself, some families pass down a genetic predisposition—a biological susceptibility to developing the condition [4]. For example, a common inherited genetic variation called the JAK2 46/1 marker is associated with a higher susceptibility to MPNs [6][7]. However, this is considered a “low-penetrance” risk factor, meaning the absolute risk remains very low and the vast majority of people who carry this genetic marker will never develop myelofibrosis [8]. It is not used as a routine clinical screening test for relatives.

When to Consider Genetic Counseling

Because strictly inherited myelofibrosis is extremely rare, genetic counseling and testing are not standard requirements for every patient [2]. However, your doctor might recommend a referral to a genetic counselor if you have certain risk factors that suggest a stronger inherited link. These situations include:

  • An unusually young age: Being diagnosed with myelofibrosis at an unusually young age (such as in your 20s or 30s) can sometimes point to an underlying inherited genetic factor [9].
  • Strong family history: Having multiple close blood relatives (parents, siblings, or children) who have been diagnosed with an MPN, leukemia, or other unexplained blood disorders [9]. Most relatives will remain unaffected even with familial clustering, but a counselor can review the specific diagnoses and ages to see if testing is warranted.
  • Planning for a stem cell transplant: If you are considering an allogeneic stem cell transplant and a family member is being evaluated as a potential donor, the transplant team may consider genetic evaluation if your history raises concern for a hereditary predisposition [9][2]. This is not required for every family donor, but it helps ensure a donor does not carry a high-risk inherited mutation. (Note: Relatives are not tested for your acquired JAK2, CALR, or MPL mutations, as those are not inherited).

What Family Members Should Do

Without a strong family history or a known inherited genetic syndrome, routine genetic testing for relatives is generally not recommended [2]. Family members should not seek out direct-to-consumer genetic testing for JAK2, CALR, or MPL on their own.

If you do have a strong family history and decide to undergo genetic counseling, the focus will be on testing your own DNA first to see if you carry a rare germline mutation. Because your blood contains the cancer cells, testing usually requires confirming any findings with DNA from a sample that does not contain blood cells. Saliva or cheek swabs can sometimes contain blood cells, so genetics teams often prefer more reliable samples like cultured skin fibroblasts [10]. Your specialist will determine the appropriate test. Only if a specific, high-risk inherited mutation is confirmed in your body would a genetic counselor discuss testing your relatives.

For now, the most practical step your relatives can take is to inform their primary care doctor about your family history. They do not need special blood count monitoring unless a clinician recommends it, but they should seek medical evaluation if they develop persistent unexplained symptoms (like severe fatigue, unusual bruising or bleeding, or recurrent infections) or if an abnormal blood count is found for another reason.

Common questions in this guide

Can myelofibrosis be passed from a parent to a child?
In most cases, no. The JAK2, CALR, or MPL changes that drive myelofibrosis are usually acquired during life in blood-forming cells and are not present in sperm or eggs, so they are not directly passed to children. Rare inherited factors can increase susceptibility without making myelofibrosis inevitable.
Do healthy relatives of someone with myelofibrosis need genetic testing?
Usually not. Routine testing for JAK2, CALR, or MPL is not recommended for relatives because the disease-driving changes are typically acquired, not inherited. A hematologist or genetic counselor may recommend testing if there is a strong family history, an unusually young diagnosis, or a suspected inherited condition.
What does a JAK2, CALR, or MPL mutation mean for my children’s risk?
When one of these mutations is found on a standard blood or bone marrow panel, it is usually an acquired change in the person’s blood-forming cells. It generally does not mean that children inherited the mutation or are destined to develop myelofibrosis. A specialist can assess whether separate testing for an inherited change is appropriate.
When should someone with myelofibrosis see a genetic counselor?
Genetic counseling may be appropriate when myelofibrosis is diagnosed unusually early, when several close relatives have myeloproliferative neoplasms, leukemia, or unexplained blood disorders, or when a family member is being considered as a stem cell donor. The counselor reviews diagnoses and ages in the family and decides whether inherited testing is warranted.
What should my relatives do if they are worried about myelofibrosis?
They should tell their primary care doctor about the family history rather than ordering direct-to-consumer genetic tests on their own. Special blood count monitoring is usually unnecessary unless a clinician recommends it, but persistent severe fatigue, unusual bruising or bleeding, recurrent infections, or an unexplained abnormal blood count should be evaluated.

Get notified when new evidence is published on myelofibrosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (10)
  1. 1

    Genetic basis and molecular profiling in myeloproliferative neoplasms.

    Luque Paz D, Kralovics R, Skoda RC

    Blood 2023; (141(16)):1909-1921 doi:10.1182/blood.2022017578.

    PMID: 36347013
  2. 2

    Germline predisposition in myeloproliferative neoplasms.

    Chernoff M, Drazer MW

    Seminars in hematology 2026; (63(2)):71-80 doi:10.1053/j.seminhematol.2026.06.006.

    PMID: 42509137
  3. 3

    Familial MPN Predisposition.

    Tashi T, Swierczek S, Prchal JT

    Current hematologic malignancy reports 2017; (12(5)):442-447 doi:10.1007/s11899-017-0414-x.

    PMID: 29027642
  4. 4

    Germline genetic factors in the pathogenesis of myeloproliferative neoplasms.

    Bellanné-Chantelot C, Rabadan Moraes G, Schmaltz-Panneau B, et al.

    Blood reviews 2020; (42()):100710 doi:10.1016/j.blre.2020.100710.

    PMID: 32532454
  5. 5

    The roles of sex and genetics in the MPN.

    Moliterno AR, Braunstein EM

    International review of cell and molecular biology 2022; (366()):1-24 doi:10.1016/bs.ircmb.2021.08.001.

    PMID: 35153002
  6. 6

    The Contribution of JAK2 46/1 Haplotype in the Predisposition to Myeloproliferative Neoplasms.

    Paes J, Silva GAV, Tarragô AM, Mourão LPS

    International journal of molecular sciences 2022; (23(20)) doi:10.3390/ijms232012582.

    PMID: 36293440
  7. 7

    Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms.

    Hinds DA, Barnholt KE, Mesa RA, et al.

    Blood 2016; (128(8)):1121-8 doi:10.1182/blood-2015-06-652941.

    PMID: 27365426
  8. 8

    Germline genetic variants that predispose to myeloproliferative neoplasms and hereditary myeloproliferative phenotypes.

    Lim J, Ross DM, Brown AL, et al.

    Leukemia research 2024; (146()):107566 doi:10.1016/j.leukres.2024.107566.

    PMID: 39316992
  9. 9

    Donor selection for allogeneic hematopoietic cell transplant in a patient with JAK2 V617F primary myelofibrosis and SH2B3/LNK germline variant.

    Ranucci G, Page C, Marchionni E, et al.

    Annals of hematology 2024; (103(12)):5999-6002 doi:10.1007/s00277-024-06140-w.

    PMID: 39672944
  10. 10

    The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis.

    Pettersson H, Adamsson J, Johansson P, et al.

    Frontiers in oncology 2023; (13()):1190305 doi:10.3389/fonc.2023.1190305.

    PMID: 37637067

This page explains inherited risk and genetic testing in myelofibrosis for informational purposes only and does not constitute medical advice. Discuss your family history, test results, and any donor evaluation with your hematologist or a genetic counselor.